April 2012, 8:29,
Open Access This content is freely available online to anyone, anywhere at any time.
Date: 24 Apr 2012
Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study
The 5% Lidocaine patch is used for treating chronic neuropathic pain conditions such as chronic back pain (CBP), diabetic neuropathy and complex regional pain syndrome, but is effective in a variable proportion of patients. Our lab has reported that this treatment reduces CBP intensity and associated brain activations when tested in an open labelled preliminary study. Notably, effectiveness of the 5% Lidocaine patch has not been tested against placebo for treating CBP. In this study, effectiveness of the 5% Lidocaine patch was compared with placebo in 30 CBP patients in a randomised double-blind study where 15 patients received 5% Lidocaine patches and the remaining patients received placebo patches. Functional MRI was used to identify brain activity for fluctuations of spontaneous pain, at baseline and at two time points after start of treatment (6 hours and 2 weeks).
There was no significant difference between the treatment groups in either pain intensity, sensory and affective qualities of pain or in pain related brain activation at any time point. However, 50% patients in both the Lidocaine and placebo arms reported a greater than 50% decrease in pain suggesting a marked placebo effect. When tested against an untreated CBP group at similar time points, the patch treated subjects showed significantly greater decrease in pain compared to the untreated group (n = 15).
These findings suggest that although the 5% Lidocaine is not better than placebo in its effectiveness for treating pain, the patch itself induces a potent placebo effect in a significant proportion of CBP patients.
Luo Z, Yu M, Smith SD, Kritzer M, Du C, Ma Y, Volkow ND, Glass PS, Benveniste H: The effect of intravenous lidocaine on brain activation during non-noxious and acute noxious stimulation of the forepaw: a functional magnetic resonance imaging study in the rat. Anesth Analg 2009, 108:334–344.PubMedCrossRef
Gammaitoni AR, Alvarez NA, Galer BS: Pharmacokinetics and safety of continuously applied lidocaine patches 5%. Am J Health Syst Pharm 2002, 59:2215–2220.PubMed
Nicolaou A, Nicholson B, Hans G, Brasseur L: Outcome predictors for treatment success with 5% lidocaine medicated plaster in low back pain with neuropathic components and neuropathic pain after surgical and nonsurgical trauma. J Pain Res 2011, 4:25–38.PubMed
Dworkin RH, Jensen MP, Gould E, Jones BA, Xiang Q, Galer BS, Gammaitoni AR: Treatment Satisfaction in Osteoarthritis and Chronic Low Back Pain: The Role of Pain, Physical and Emotional Functioning, Sleep, and Adverse Events. J Pain 2010, 12:416–424.
- Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
- Online Date
- April 2012
- Online ISSN
- BioMed Central
- Additional Links
- Chronic pain
- Clinical trial
- Topical analgesic
- Author Affiliations
- 1. Department of Physiology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, 60611, USA
- 2. Department of Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, 60611, USA
- 3. Department of Anesthesia, Surgery, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, 60611, USA